FDA

Rand Paul's Biosimilar Drug Bill Could Cut Costs, Speed Patient Access

The Expedited Access to Biosimilars Act enables FDA approval of pharmaceutically equivalent biologic medications.

Ronald Bailey | 7.31.2026 1:20 PM

Share on FacebookShare on XShare on RedditShare by emailPrint friendly versionCopy page URL Add Reason to Google

Media Contact & Reprint Requests

(Michael Brochstein/Sipa USA/Newscom/senate.gov)

Sen. Rand Paul's (R–Ky.) proposed Expedited Access to Biosimilars Act was unanimously voted out of the Senate Health, Education, Labor, and Pensions (HELP) Committee last week. This is good news.

Biosimilars are medications that are highly similar to biologic medications that have already been approved by the Food and........

© Reason.com